In the BioHarmony Drug Report Database

"Preview" Icon

Raloxifene

Evista, Optruma (raloxifene) is a small molecule pharmaceutical. Raloxifene was first approved as Evista on 1997-12-09. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat postmenopausal osteoporosis. The pharmaceutical is active against estrogen receptor and estrogen receptor beta. In addition, it is known to target G-protein coupled estrogen receptor 1 and estrogen receptor beta.

 

Trade Name

 

Evista, Optruma
 

Common Name

 

raloxifene
 

ChEMBL ID

 

CHEMBL81
 

Indication

 

postmenopausal osteoporosis
 

Drug Class

 

Antiestrogens of the clomifene and tamoxifen groups

Image (chem structure or protein)

Raloxifene structure rendering